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Abstract
Potency testing is an important part of the evaluation of cellular therapy products. Potency assays
are quantitative measures of a product-specific biological activity that is linked to a relevant
biological property and, ideally, a product's in vivo mechanism of action. Both in vivo and in vitro
assays can be used for potency testing. Since there is often a limited period of time between the
completion of production and the release from the laboratory for administration to the patient, in
vitro assays such are flow cytometry, ELISA, and cytotoxicity are typically used. Better potency
assays are needed to assess the complex and multiple functions of cellular therapy products, some
of which are not well understood. Gene expression profiling using microarray technology has been
widely and effectively used to assess changes of cells in response to stimuli and to classify cancers.
Preliminary studies have shown that the expression of noncoding microRNA which play an
important role in cellular development, differentiation, metabolism and signal transduction can
distinguish different types of stem cells and leukocytes. Both gene and microRNA expression
profiling have the potential to be important tools for testing the potency of cellular therapies.
Potency testing, the complexities associated with potency testing of cellular therapies, and the
potential role of gene and microRNA expression microarrays in potency testing of cellular
therapies is discussed.
Background
Cellular therapies are making a major contribution to the
emerging field of biologic therapy. The possibilities for
the clinical application of new cellular therapy products
are expanding rapidly as is their clinical promise. The
diversity and effectiveness of cellular therapies that are
now available has encouraged the development of new
clinical applications and improved the quality of life of
patients. These therapies include adoptive immune ther-
apy utilizing enriched or in vitro manipulated autologous
or allogeneic immune cells to treat cancer and viral infec-
tions [1,2]; β islet cell transplantation [3], hematopoietic
progenitor cells (HPC) for transplantation; HPC therapy
for cardiac ischemia [4,5], and gene therapy [6]. As this
field matures, the ability to produce large quantities of
biological products with predictable quality and quantifi-
able potency is becoming critical.
The complexity of cellular therapies is also increasing as
new knowledge about the function of specific cell types
and their biologic status becomes available. For example,
the initial adoptive immune therapy protocols to treat
cancer once only involved the administration of autolo-
gous tumor infiltrating leukocytes (TIL) [7] or leukocyte
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activated killer cells (LAK) [8]. Now adoptive immune
therapy protocols are combination therapies that include
high dose chemotherapy, the administration of in vitro
activated and primed TIL, and autologous HPCs [9].
Immunosuppressive chemotherapy depletes the patient's
naturally occurring repertoire of lymphocytes including T
regulatory cells. The lack of T regulatory cells and
increased levels of cytokines, including IL-7, that are asso-
ciated with leukopenia allow for the rapid and marked in
vivo expansion of TIL administered with hematopoietic
progenitor cells HPCs [9].
Similarly, HPC transplants have become more complex.
While hematopoietic progenitor cell transplants (HPCTs)
have been used successfully to treat leukemia for more
than 30 years, this therapy has been constantly evolving.
These changes involve tailoring and optimizing its efficacy
by using HPC transplantation in combination with
immune therapy to treat leukemia. Either manipulated or
unmanipulated lymphocytes from HCPT donors are often
administered to recipients following transplantation to
prevent or treat disease relapse and enhance immune
recovery [10,11].
The sources of hematopoietic progenitor cells used for
transplantation have also changed. Early HCPTs were per-
formed exclusively using bone marrow as a source of pro-
genitors. Now, in addition to bone marrow, G-CSF-
mobilized progenitors collected from the peripheral
blood by apheresis and umbilical cord blood (UCB) are
used for HPCT.
Many clinical cellular therapy products require cell mobi-
lization, collection, subset isolation, in vitro or  in vivo
stimulation, and culture of cells over a period of several
days. The production of some cellular therapies involves
serial isolation steps and multiple stimulation and/or cul-
turing steps. Cellular therapy product manufacture is fur-
ther complicated by donor or patient genetic and
physiological heterogeneity. The final product is often
markedly different from the starting material. Because of
the complex nature of producing cellular therapy products
and the clinical importance of the final products, most
institutes conducting cellular therapy have developed spe-
cialized good manufactory product (GMP) laboratories
devoted to the production of these therapeutic agents. The
goal of these cell processing laboratories is to produce cel-
lular therapy products that provide the desired clinical
affect without resulting in adverse effects. These special-
ized laboratories ensure that an adequate dose of cells is
provided to each patient, each product meets release spec-
ifications, and lot-to-lot variation is minimized. In order
to produce consistently high quality products, quality
assurance has become a critical part of cellular therapy
laboratories.
All cellular therapy products must be demonstrated to be
safe, pure, potent, stable, and effective for human use.
Objective standards based on clinical trial and manufac-
turing data should be established to evaluate safety and
quality characteristics of clinical products during produc-
tion and at the time of lot release. Also known as product
specifications, these standards are intended to ensure that
cellular products consistently meet regulatory and indus-
try requirements for sterility, safety, purity, identity, and
potency. Tests to measure and evaluate these parameters
are performed at critical steps in the manufacturing proc-
ess (in-process testing) and at the end of the production
prior to the release of the product for clinical use (lot
release testing). The results of in-process and lot release
assays should fall within specified ranges and meet prede-
termined acceptance criteria before the product can be
released for human use. In-process testing and lot release
testing are important for assuring individual product
quality as well as lot-to-lot consistency. For cellular thera-
pies, these assays include tests of sterility, including myc-
oplasma, viability, and assessment of product potency.
One of the most important aspects of assessing the quality
of cellular therapy products is to ensure that all products
meet established minimal levels or ranges of potency and
that potency levels are consistent across manufacturing
lots.
Potency testing
Potency testing involves the quantitative measure of bio-
logical activity of a product. The biological activity
describes the ability of a product to achieve a defined bio-
logical effect. Potency testing is the quantitative measure
of a biological activity which is linked to relevant biolog-
ical properties of a product. The biological activity meas-
ured should be closely related to the product's intended
biological effect and ideally it should be related to the
product's clinical response [12-14].
Potency assessments are meant to measure a cellular ther-
apy product's critical biological activity within a complex
mixture by quantifying the product's activity in a biologi-
cal system. Measurement of the potency of a product is
not the same as measuring clinical efficacy, but rather a
means to control product consistency. Generally, potency
testing is performed at the time of product lot release and
across all production lots.
Since potency assays for cellular products usually take a
considerable amount of time to develop, generally, the
development of potency assays is progressive. The devel-
opment of potency assays usually begins during preclini-
cal and early clinical development. Development starts
with identifying the critical biological activity of the prod-
uct and formulation of an approach to potency determi-Journal of Translational Medicine 2007, 5:24 http://www.translational-medicine.com/content/5/1/24
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nation. A potency assay should be validated prior to phase
III clinical trails [12,13].
Complexities associated with potency testing of cellular 
therapies
Potency testing of cellular therapies is particularly chal-
lenging for several reasons (Table 1). First of all, since
most cellular therapies are patient-specific, there is usually
a limited quantity of suitable source material and, there-
fore, a limited amount of final ready to administer bio-
logic material to use for lot release and potency testing.
The starting materials for most cellular therapies are cells
collected from human subjects. The subjects may be the
person being treated, autologous products, or a living
donor, allogeneic products. For both situations the quan-
tity of starting material that can be collected is limited and
consequently the amount of material produced is limited.
As a result an entire production lot of a cellular therapy is
usually administered to a single patient and the use of
large quantities of the product for lot release testing may
adversely affect the dose and clinical effectiveness of the
product. This limitation on the quantity of material avail-
able prevents the use of some assays and/or limits the
number of analytes that can be tested.
Second, the time to test the product is limited since cellu-
lar therapy products must be tested at the time production
is complete, but prior to being released for clinical use.
This is particularly problematic for cellular therapies since
the potency of many living cells is affected by prolonged
storage at physiological temperatures. In fact, some prod-
ucts must be administered within hours upon production
completion. In addition, handling affects the potency of
some products.
Most potency assays require reference preparations with
an established potency which are used as assay standards
[12]. The limited availability of reference standards com-
plicates potency testing for cellular therapies. Often "in-
house" reference standards must be developed. When ref-
erence standard are commercially available, they are may
be expensive.
Finally, cellular therapy products typically show a large
degree of lot-to-lot variability. Product variability is due in
part to inherent variability in the starting cells or tissues.
Donor genetic factors likely contribute to differences in
potency of the final cellular therapy product. Genetic pol-
ymorphisms in cytokines, growth factors and their recep-
tors affect the cellular immune response [15-18]. It is
likely that these polymorphisms affect the response of
cells to cytokine and growth factor stimulation in vitro and
the behavior of cells during culture. Epigenetic changes
may also be important. The same type of cells obtained
from different donors at different time points and under
different physiological conditions could vary significantly
due to genetic heterogeneities, epigenetic differences, or
transcription regulation diversities.
Factors affecting the potency of cellular therapies
Despite the difficulties associated with potency testing of
cellular therapies, potency is particularly important for
these products since the complexities associated with their
production can result in considerable differences in
potency among different lots of the same product (Table
2). These differences are related to the multiple steps
required to produce most cellular therapies, variations in
starting materials, limited stability of the final product,
complex mechanisms of action of the product, and
genetic differences among individuals donating the start-
ing cells.
Advanced cellular therapies may incorporate multiple
components. For example, cellular products used for can-
cer vaccines may require more than one peptide to edu-
cate immune cells in vitro, followed by cytokine
stimulation. A manipulated lymphocyte component pre-
pared for a HPCT donor may involve isolating and recom-
bining multiple different types of cells. The multiple cell
types present in many cellular therapies have the potential
to interfere with one another or to act synergistically.
Many cellular therapies are subject to extensive manipula-
tion, including manufacturing processes such as cytokine,
growth factor or antigen stimulation; culture; expansion;
and treatment with vectors or toxins. For these products,
slight variations in the starting cellular material, reagents,
processing methods, or culture conditions may result in
significant variation in the final product leading to heter-
ogeneous clinical out comes of the same therapies.
Table 2: Factors contributing to the complex nature of cellular 
therapies
▪Variations in the starting cellular material
▪Multiple biological products may be used in the manufacturing 
process
▪Multiple steps can be involved in the manufacturing process
▪Clinical effectiveness may be dependent on multiple cellular functions
Table 1: Challenges associated with potency testing of cellular 
therapies
▪Limited quantity of final product to test
▪Time to perform lot release testing is usually limited
▪Stability of most cellular therapy products is limited
▪Limited availability of reference standards
▪Variability among lots is generally very highJournal of Translational Medicine 2007, 5:24 http://www.translational-medicine.com/content/5/1/24
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Finally, the in vivo function of most cellular therapies is
dependent on multiple factors in the host environment.
Hematopoietic stem cells must traffic to specific sites,
expand, and differentiate into several mature cell types.
Immune therapies must migrate from the site of adminis-
tration, interact with tumor or other immune cells, and
respond to stimuli and/or stimulate other cells.
Measuring potency of cellular therapies
Potency can be tested in a number of ways including in
vivo and in vitro systems (Table 3). Testing potency using
in vivo animal models is generally preferred over in vitro
test systems since animal models assays have the ability to
directly measure a product's functional activity. However,
existing animal models may not be relevant and new ani-
mal models may be difficult to develop [12]. In addition,
the results of in vivo tests are often variable and difficult to
reproduce. Furthermore, these assays usually take a con-
siderable amount of time to complete making it difficult
to use these assays for routine lot release testing. Many in
vivo assays are best suited for use in product development,
as an in-process control, or to evaluate the potential effect
of changes in the manufacturing process or materials [13].
In vitro assays involve the measurement of biochemical or
physiological responses at the cellular level [12]. The in
vitro  measurement of cell surface markers, activation
markers, secretion of factors, or protein expression do not
directly measure the function of a cellular product, how-
ever, they have been used as surrogates for potency. When
an in vitro assay is used as a surrogate for potency, a corre-
lation should be demonstrated between the assay results
and the intended biological activity. Typical in vitro assays
used as surrogates for potency testing include ELISA, ELIS-
POT, flow cytometry, proteomic analysis and cytotoxicity
assays.
When the mechanism of action of a cellular therapy can
be attributed to the expression of specific cell surface anti-
gens, the measurement of antigens by flow cytometry can
be used as an in vitro potency assay. In fact, the measure-
ment of biomarkers by flow cytometry is often used as a
surrogate measure of cell potency. Flow cytometry is use-
ful due to the large number of reagents and assays that are
available as well as the relatively quick turn around time.
It can be used to measure the expression of cell surface
markers, viability, and the production of cytokines. Exten-
sive analysis of cell surface markers using flow cytometry
has been used to assess cellular therapies, but the maxi-
mum number of makers that can be analyzed is limited by
the availability of specific antibodies, instrumental detec-
tion limits, and final product quantity. In addition, the
markers that maybe most useful may not be known
In vitro cell function assays have also been used to meas-
ure cell potency. Cytotoxicity assays are sometimes used
to reflect the function of adoptive immune therapies.
Cytokine release by stimulated cells can also be used to
measure cell function. However, cell function assays have
many limitations. While they maybe able detect differ-
ences in relevant biological activity, these assays are typi-
cally highly specialized for each cell type, labor intensive,
and require highly skilled staff. Different types of cells and
cell subsets require completely different types of cell func-
tion technologies. Many cells require the measurement of
multiple functions to adequately assess potency. Further-
more, the function(s) which best predict cell potency may
not be known. In fact, for many cellular therapies, all
aspects that contribute to in vivo activity are not com-
pletely understood. In addition to these limitations, many
cell processing laboratories working with cellular thera-
pies in phase I and II clinical trials prepare several differ-
ent types of cellular therapies. It is possible, but may not
always be feasible for a centralized cell processing labora-
tory to perform several different types of cell function
assays.
Cell counts and viability measurements are often pre-
formed on cellular therapies. However, since these assays
do not measure a relevant biological activity, they are not
potency measures [12,13].
Gene expression microarrays for potency testing
Measurements of the expression of genes related to a spe-
cific cellular activity or function could be used as an in
vitro  biomarker of potency. Quantitative real-time PCR
assays are useful tools for assessing the expression of indi-
vidual genes in order to assess the activity of immune
cells. The measurement of changes in interferon gamma
transcription by quantitative real-time PCR has been used
to as a marker for T cell activation following stimulation
with a recall antigen [19-22]. Quantitative real-time PCR
has recently been used to measure the production of
mRNA encoding interferon-γ, interleukin-2 (IL-2), IL-4
and IL-10 by stimulated T cells [20]. Quantitative real-
time PCR arrays are also available to assess angiogenesis,
apoptosis, cell cycle, insulin signaling pathways, cytokines
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and receptors, nitric oxide signaling pathways and JAK/
STAT signaling pathways.
While using quantitative real-time PCR to measure the
expression of single genes or groups of genes is helpful in
assessing cell function, the complete assessment of the
function of cellular therapies requires the measurement of
a broad range of gene transcripts, especially when the
mechanisms responsible for effective therapy are not thor-
oughly understood. The analysis of cells using gene
expression microarrays allows the simultaneous assess-
ment of the expression of thousands of genes. One practi-
cal advantage of gene expression microarray assays over
other analytical assays is that very few cells are needed.
Enough RNA can be isolated from 1 × 104 to 1 × 106 cells
for analysis with a 17,500 gene cDNA expression microar-
ray [23].
Microarrays with 15,000 to 40,000 genes or oligonucle-
otide probes have been used clinically to characterize lym-
phomas [24], prostate cancer [25], ovarian cancer [26],
small cell lung cancer [27], and melanoma [28] and many
other cancers. We have used cDNA gene expression micro-
arrays with 17,500 genes to investigate the immunologic
changes associated with high dose IL-2 therapy for renal
cell carcinoma [29] and imiquimod, a TLR-7 ligand, ther-
apy for basal cell carcinoma [30]. We have also used
cDNA microarrays to assess the effects of IL-10 on NK cells
[31-33] and several different types of interferon on LPS-
stimulated mononuclear cells, the in vitro response of
mononuclear cells to IL-2 [34], and the molecular basis of
cutaneous wound healing [35].
While gene expression microarrays have been widely used
to assess changes in cells in response to stimuli, or to clas-
sify different types of cancers, they have only been used to
a limited extent to assess cell potency. However, since
gene expression microarrays simultaneously measure the
expression of thousands of genes, they capture a snap shot
of all possible gene expression signatures which are asso-
ciated with cellular function and hence could be a very
important tool for assessing the potency of cellular thera-
pies. The comprehensive nature of gene expression micro-
array analysis makes them ideal for measuring both
expected and unexpected cell functions. This is particu-
larly important for the analysis of cells with complex and
multiple critical functions such as dendritic cells (DCs),
embryonic stem cells, and hematopoietic stem cells.
In addition to assessing potency, gene expression microar-
rays can also assess other important aspects of cellular
therapy products such as stability, purity, maturation and
differentiation status. Since microarrays can detect the
activation of apoptosis pathways that signal the onset of
cell death, they have the potential to provide useful infor-
mation concerning the effects of storage or manipulation
on cell viability. The assessment of the expression of apop-
tosis genes is likely to be much more sensitive in assessing
cell viability than dye exclusion assays or the flow cyto-
metric measurement of Fas or annexin. Gene expression
profiles can also detect subpopulation of cells and there-
fore provide information concerning cell purity.
There are some limitations concerning the use of gene
expression microarrays for potency testing. Gene expres-
sion microarray analysis involves multiple steps including
RNA isolation, amplification, fluorescent labeling,
hybridization and data analysis. It is impossible at the cur-
rent technology stage to complete the whole procedure
within a few hours and so these global expression micro-
arrays can not yet be used for lot release testing. However,
if global microarrays can identify specific sets of gene
whose expression is associated with potency, tailored
chips or quantitative real-time PCR kits which only assess
specific "potency genes" could be developed and used for
lot release testing.
Potential applications of gene expression profiling for 
potency testing
Predicting the confluence of human embryonic kidney 293 cells
Gene expression microarrays have been demonstrated to
be useful for some cell therapy applications. They can be
used to predict the quality of cells used to manufacture
biologic products. Human embryonic kidney (HEK) 293
cells are often used to manufacture products such as ade-
noviral gene therapy vectors and vaccines [36]. These cells
can be grown in bioreactors, tissue culture flasks, and
roller bottles. However, when HEK 293 cells grow to form
a confluent monolayer, their phenotype changes as does
the quality of the vector or vaccine produced by these
cells. Cell confluence can be readily assessed by visual
inspection of cells grown in flasks and roller bottles, but
for cells grown in bioreactors, the assessment of conflu-
ence by visual inspection is not always possible. Gene
expression profiling has been used to identify genes
whose expression predicts cell confluence [36]. Human
embryonic kidney 293 cells that have been grown to 90%
confluence have a unique gene expression signature com-
pared to those grown to 40% confluence. A set of 37 of
these signature genes is able to predict that quality and
confluence of HEK 293 cells. While this use of gene
expression profiling does not represent a potency assay, it
demonstrates the potential of the use of gene expression
profile assays.
Cell differentiation status analysis of embryonic stem cells
Human embryonic stem cells (hESC) have the potential
to be useful for a number of clinical applications. Since
cultured hESC may undergo spontaneous differentiation,
it is important to determine if cultured hESC have main-Journal of Translational Medicine 2007, 5:24 http://www.translational-medicine.com/content/5/1/24
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tained their stem cell qualities or if they have begun to
acquire properties of more differentiated cells. Gene
expression profiling may be useful for assessing cultured
hESC. Gene expression profiling has been used to identify
genes that are uniquely expressed by hESC [37]. Player et
al have found that 1715 genes were differentially
expressed between hESC and differentiated embryonic
cells [37]. The analysis of the expression of genes that are
expressed by hESC but not by differentiated cells is likely
to be useful in determining if cells in culture have main-
tained their embryonic stem cell characteristics.
Embryonic stem cells must be differentiated before they
can be used clinically. One of the first steps in the differ-
entiation of hESC into mature cells and tissues for clinical
use is the production of embryoid bodies (hEB). The pro-
duction of embryiod bodies involves the aggregation of
embryonic cells but the prevention of separation of cells
into germ lines by plating them onto a non-permissive
substrate. After these hEB are isolated they can be induced
to generate several different types of cells including
hematopoietic cells, neuronal, myogenic, and cardiac
muscle cells. A comparison of genes expression profiles of
hESC and hEB has found that the expression of several
genes were down regulated and several were upregulated
including 194 whose expression was more than 3-fold
greater in hEB [38]. This unique set of genes should also
be useful in assessing hESC differentiation.
Potency testing of hematopoietic progenitors
While hESC are not yet being used for clinical applica-
tions, hematopoietic stem cells are widely used for several
clinical applications and better potency assays for these
therapies are needed. Potency assays for hematopoietic
stem cell products used for transplantation should meas-
ure the ability of the product to reconstitute bone marrow
hematopoietic cells and peripheral blood cells in the
transplant recipient. The potency assay should reflect the
period of time that neutrophil, platelet, and red blood
cells counts return to and remain above specified levels
independent of transfusion therapy. In another words if
the potency assay indicates that a product meets mini-
mum criteria, the therapy should result in at least mini-
mum acceptable neutrophil, platelet, and RBC counts in
the recipient for a minimum specified duration of time.
Liquid culture of long-term culture initiating cells (LTC-
IC) and the repopulation of marrow in nonobese diabetic
(NOD)/severe combined immunodeficiency (SCID) mice
assays are considered to be the best measure of the quan-
tity and quality of hematopoietic stem cells. However,
these assays require several weeks to complete, highly spe-
cialized reagents, and highly trained staff. As a result these
assays have seldom, if ever, been used as potency assays.
The measurement of myeloid, erythroid, and mixed col-
ony formation in methylcellulose culture systems has
been the standard method for assessing bone marrow and
PBSC concentrates, but they have been used mainly as in-
process controls. The measurement of colony formation
in methyl cellulose is an effective biological assay that
directly measures a relevant function of HPCs, however,
these assays take approximately 14 days to complete and
consequently they can not be used as a potency assay.
Traditionally, total nucleated cells counts were used to
assess the potency of bone marrow and are still used as a
measure of potency of UCB components prepared for
transplantation. Regulations suggest that UCB compo-
nents contain ≥ 90 × 107 total nucleated cells including
nucleated RBC and that ≥ 85% of nucleated cells are viable
[39]. However, the measurement of CD34+ cells by flow
cytometry, has become the universal assay for measuring
the potency of HPC products collected by apheresis from
subjects treated with hematopoietic growth factors. The
number of CD34+ cells in a HPC product can be meas-
ured within a few hours using anti-CD34 and flow cytom-
etry and this assay is well-suited for lot release testing.
Generally, a dose of 1 × 106 per kg of CD34+ G-CSF-mobi-
lized peripheral blood stem cells (PBSCs) is considered
adequate for an autologous transplant and 3 to 5 × 106
CD34+ cells per kg for an allogeneic transplant. Umbilical
cord blood components must on contain ≥ 1.25 × 106 via-
ble CD34+ cells.
While CD34 antigen expression is widely used as a meas-
ure of potency of HPCs collected from the peripheral
blood, HPCs expressing CD34 antigen do not represent a
homogenous population. Several distinct subpopulations
or phenotypes of CD34+ cells have been described [40].
Some subpopulations are more primitive, while others are
more likely to different into myeloid cells, erythroid cells
or megakaryocytes.
Despite the heterogeneity of CD34+ cells, the measure-
ment of CD34+ cells has been an effective measurement
of potency of PBSC concentrates collected by apheresis.
This is likely because PBSC components are relatively sim-
ilar in that almost all PBSC components are collected
from subjects given granulocyte colony-stimulating factor
(G-CSF) alone or in combination with chemotherapy.
However, the sources of stem cells and types of mobilizing
agents used for transplantation are changing. UCB com-
ponents are being used in place of PBSC concentrates and
marrow for unrelated donor HPC transplantation. A new
stem cell mobilizing agent, AMD3100, is being used with
G-CSF to mobilize stem cells for autologous transplants
[41] and will likely soon be used for allogeneic donor
transplants [42,43]. CD34+ cells from both UCB and
AMD3100-mobilized PBSC concentrates differ fromJournal of Translational Medicine 2007, 5:24 http://www.translational-medicine.com/content/5/1/24
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those found in G-CSF-mobilized PBSC concentrates and
the quantity of CD34+ required for a successful transplant
from some of these types of products will likely differ
from the quantity required for a successful G-CSF-mobi-
lized PBSC transplant.
AMD3100 mobilizes stem cells by a different mechanism
than G-CSF. AMD3100 is a CXCR4 antagonist and it
mobiles stem cells within 6 hours by disrupting the bind-
ing of stem cell CXCR4 with SDF-1, CXCL12, on marrow
osteoblasts [44]. In contrast G-CSF mobilizes stem cells
indirectly by down regulating the expression of SDF-1 on
marrow osteobasts and by releasing neutrophil and
monocyte proteolytic enzymes including neutrophil
elastase, cathepsin G, and maxtrix metalloproteinase-9
that degrade important HPC trafficking and adhesion
molecules c-kit, VCAM-1, CXCR4, and SDF-1 [44].
Because of the differences in mechanisms of mobilization
between AMD3100 and G-CSF, AMD3100 mobilizes a
CD34+ cell population with a greater long-term marrow
repopulating capacity and with a different phenotype
than G-CSF [43].
The potency of UCB CD34+ cells also differs from that of
G-CSF-mobilized peripheral blood CD34+ cells. The
potency of CD34+ cells from UCB as measured by the
ability to repopulate NOD SICD mice is greater than the
potency of CD34+ cells from bone marrow or G-CSF
mobilized PBSCs [45-47]. In addition, UCB CD34+ cells
show increased proliferative capacity compared to bone
marrow and G-CSF-mobilized PBSC CD34+ cells in meth-
ycellulose culture [47-49].
Since the potency of CD34+ cells is dependent on the
number of and subtypes of CD34+ cells and since the
sources of hematopoietic progenitor cells used in trans-
plantation is increasing, new potency assays are needed.
Preliminary comparison of CD34+ cells mobilized by G-
CSF and G-CSF plus AMD3100 using gene expression pro-
filing has identified 81 genes whose expression in 3 sub-
jects was increased in G-CSF plus AMD-3100 mobilized
CD34+ cells and 29 genes whose expression was
decreased [50]. Genes whose expression was increased
included those involved with anti-apoptosis, cell cycle,
replication/DNA repair, cell mobilization and oxygen
transport. Further work is needed to identify HPC genes
whose expression best correlates with the results of tradi-
tional potency assays such as colony formation assays.
Potency testing of dendritic cells
Dendritic cells (DCs) are potent professional antigen pre-
senting cells capable of capturing and processing antigens
in order to present peptides to prime T cells [51]. They
express both HLA class I and class II molecules and
present peptides to CD4+ and CD8+ T cells. They also
express co-stimulatory molecules such as CD80, CD86,
CD40, ICAM-1, and LFA-3. For immune therapy, DCs can
be generated from PBMCs after GM-CSF and IL-4 stimula-
tion in vitro, or they can be generated by co-culturing in
vitro with irradiated tumor cells or virus infected cells, pro-
teins or peptides. Mature DCs are then administered to
patients to stimulate cytotoxic T cells in vivo. Immuno-
therapies with DCs are being used to treat melanoma,
renal cell carcinoma, prostate cancer and leukemia [51].
Since few DCs are present in the blood, they must be pro-
duced from other types of cells. DCs for clinical therapies
produced from CD34+ cells are known as plasmacytoid
DCs and those produced from circulating mononuclear
cells are know as myeloid-derived DCs. Either mature or
immature DCs can be produced. Immature DCs express
lower levels of HLA class II antigens and lower levels of co-
stimulatory molecules but higher levels of Fc and man-
nose receptors. The ability of immature DCs to phagocy-
tosize and process antigens is better than that of mature
DCs, but mature DCs present antigens better than imma-
ture DCs. While the function of mature and immature
DCs differ, it is not possible with standard analytic assays
to precisely distinguish the degree of maturation of DCs.
The potency of DCs can be tested by assessing the ability
of DCs loaded with antigen to stimulate autologous T
cells [52]. However, this is difficult because of the low per-
centage of T cells in most patients that are responsive to
tumor antigens. One alternative to overcome the low
number of autologous T cells is to generate and expand T
cell clones that respond to specific antigens. Even so, only
T cells with the same HLA restriction elements and anti-
gen specificity could be used in a DC potency assay. For
example, HLA-A*0201 T cell clones specific to a
melanoma antigen such as Mart I would not be useful for
testing dendritic cells prepared from subjects with other
HLA types such as HLA-A*03 or other antigens such as
cytomegalovirus (CMV) pp65. Consequently, separate
clones must be developed for each antigen and HLA
restriction being studied.
The potency of DCs can be assessed by using test peptides
from recall antigens that are able to stimulate memory T
cell responses [52]. These antigens include HLA-restricted
tetanus toxin, influenza virus, and Epstein-Barr virus
(EBV) antigens since most people have been immunized
against these antigens. However, assays using recall anti-
gens do not directly test DCs ability to present tumor-
associated antigens and efficacy to stimulate tumor-spe-
cific T cells. So these assays can not be used as a lot release
test for DCs used for cancer therapy, although testing the
ability of DCs to present recall antigens and stimulate T
cells is useful as an in-process control.Journal of Translational Medicine 2007, 5:24 http://www.translational-medicine.com/content/5/1/24
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The measurement of DC co-stimulatory activity has been
used to measure the potency of DCs. Co-stimulation plays
a critical role in the induction of antigen-specific immu-
nity. One method to measure co-stimulation is the mixed
lymphocyte culture reaction that is based on the stimula-
tion of responder cells with replication competent alloge-
neic DC stimulator cells. However, it is not known to what
degree allo-reactivity and co-stimulation contribute to T
cell stimulation.
Alternatively, gene expression profiling is likely to be use-
ful in assessing the potency of DCs used for clinical thera-
pies. It has been used to characterize the differentiation of
monocytes into macrophages and their polarization to
macrophages with a type 1 or type 2 phenotype [53] and
has also been used to characterize the response of mono-
cytes to LPS and cytokine stimulation [32,33]. Prelimi-
nary data in our laboratory has also found that gene
expression profiling can distinguish monocytes from
immature DCs and immature DCs from mature DCs. The
ability of gene expression microarrays to assess cells glo-
bally may allow them to determine the potency of DCs by
evaluating unstimulated cells or cells that have been stim-
ulated with a recall antigen. However, genes whose
expression reflects DC maturation as well as specific DC
functions must be identified before gene expression pro-
filing can be used as a potency assay for DCs.
MicroRNAs as potency assays
MicroRNAs (miRNA) are likely to be another important
indicator of hematopietic and immune cell potency. miR-
NAs are an abundant class of endogenous non-protein-
coding small RNAs of 19 to 23 nucleotides which are
derived from pre-miRNA of 60 to 120 nucleotides. Mature
miRNAs negatively regulate gene expression at the post
transcriptional level. They reduce the levels of target tran-
scripts as well as the amount of protein encoded. 541
human miRNAs have been so far identified [54]. In gen-
eral, miRNAs are phylogenetically conserved and, there-
fore, have conserved and defined post transcription
inhibition function. Some miRNAs are expressed
throughout an organism, but most are developmentally
expressed or are tissue-specific.
MicroRNAs play an important role in many cellular devel-
opment and metabolic processes including developmen-
tal timing, signal transduction, tissue differentiation, and
cell maintenance. Most miRNAs are tissue specific. For
example the expression of miR-1 is restricted to the heart
[55] and miR-223 to granulocytes and macrophages [56].
Recently, miRNA have been found to have a role in stem
cell self renewal and differentiation. Several different miR-
NAs are involved with the differentiation of hematopoi-
etic progenitor cells. MiR-155 is important in preventing
the differentiation of CD34+ cells toward myeloid and
erythroid cells [57]. In addition, miR-221 and miR-222
prevent the differentiation of hematopoietic stem cells
into erythroid progenitors [58]. MiR-181 is involved in
the control of lymphopoiesis [56].
MicroRNA seems ideally suited for distinguishing primi-
tive from committed hematopoietic, embryonic and other
stem cells as well as different types of lymphocytes and
mononuclear phagocytes. However, they have not been
evaluated to determine if they would be useful in this
capacity. MicroRNA profiles of mononuclear phagocytes
and dendritic cells have not been studied extensively, but
if miRNA profiles differ between immature and mature
DCs, they may be useful in assessing the potency of DCs
produced in vitro.
The high throughput analysis of miRNAs requires at least
10 times greater quantities of cells than gene expression
profiling since miRNAs contribute only about 1% of a
cell's total mRNA. MiRNA amplification methods have
not yet been fully validated and, hence, are not considered
reliable. However, targeted miRNA analysis requires a rel-
atively small number of cells, 1 × 106.
An advantage of miRNA expression profiling compared to
gene expression profiling is that miRNA expression profil-
ing requires smaller arrays and chips which make it possi-
ble to analyze multiple samples on the same slides
containing sub-arrays. While gene expression cDNA
microarrays contain 10,000 to 35,000 probes, the number
of miRNA currently identified is only in the hundreds.
Conclusion
As more and more new cellular therapies are being devel-
oped and used to treat an increasing variety of diseases
and patients, potency testing is becoming a critical and
required part of the production of cellular therapies. Exist-
ing assays, such as function, flow cytometry, and ELISA are
important but limited by the number of factors analyzed.
Gene expression microarrays have the potential to
become important in potency testing. They are well suited
for the assessment of the potency of cellular therapies in
phase I and II clinical trials. As data is collected during
clinical trials the results of analysis with the gene expres-
sion microarrays should be compared with the results of
traditional function assays and genes whose expression is
associated with critical biological function identified and
used to develop assays to rapidly measure the expression
of genes associated with cell potency. While it is also
worth assessing cellular therapies in phase I and II clinical
trials with miRNA expression microarrays, the role of
miRNA profile analysis in assessing potency is yet to be
tested.Journal of Translational Medicine 2007, 5:24 http://www.translational-medicine.com/content/5/1/24
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